In a pre-clinical setting, we demonstrate spectral discrimination of two small molecule-based tumor-targeted probes: integrin-specific peptides conjugated with IRDye 680RD and EGFR-binding affibodies conjugated with IRDye 800CW. This evidence concerns the gene EGFR and neoplasm.